TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 1.94E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 110nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 3.50E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >3.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 2.07E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 313nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 5.60E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 1.40E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 100nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 6.96E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 6.30E+3nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Effect on IgE/Fcepsilon RI triggered rat basophil cell (RBL-2H3) degranulation assessed by measuring the amount of 5-HT releaseMore data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 0.893nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 2.35nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 2.79nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 3.95nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 7.26nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 7.98nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 8.33nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 8.75nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 9.47nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 12.1nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 13.9nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 14.8nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 14.9nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 15.8nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 16nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 16nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 17.7nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 18.3nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 18.6nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibitory activity against IgE receptorMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibitory activity against IgE receptorMore data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibitory activity against IgE receptorMore data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 22nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 25.3nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 28.7nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 100-...More data for this Ligand-Target Pair
TargetLow affinity immunoglobulin epsilon Fc receptor(Human)
Aventis Pharmaceuticals
Curated by ChEMBL
Aventis Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line); value ranges from 30-1...More data for this Ligand-Target Pair
TargetType-2 angiotensin II receptor/Low affinity immunoglobulin epsilon Fc receptor(Human)
Confo Therapeutics
US Patent
Confo Therapeutics
US Patent
Affinity DataIC50: 32.6nMAssay Description:All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human A...More data for this Ligand-Target Pair

















































